ACTIVITY OF FLUDARABINE IN REFRACTORY CHRONIC LYMPHOCYTIC-LEUKEMIA AND LOW-GRADE NON-HODGKINS-LYMPHOMA - THE JERUSALEM EXPERIENCE

被引：17

作者：

GILLIS, S ^{[1
]}

DANN, EJ ^{[1
]}

CASS, Y ^{[1
]}

ROCHLEMER, R ^{[1
]}

POLLIACK, A ^{[1
]}

机构：

[1] HEBREW UNIV JERUSALEM,HADASSAH MED SCH,MED CTR,DEPT HEMATOL,LYMPHOMA & LEUKEMIA UNIT,IL-91010 JERUSALEM,ISRAEL

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 15卷 / 1-2期

关键词：

FLUDARABINE; REFRACTORY LYMPHOCYTIC LEUKEMIA; REFRACTORY LYMPHOMA; CHRONIC LYMPHOCYTIC LEUKEMIA;

D O I：

10.3109/10428199409051694

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty four patients with refractory chronic lymphocytic leukemia (CLL) and advanced low grade lymphoma (LGL) were treated with Fludarabine given at a dose of 25 mg/m(2), intravenously daily for 5 days, every 28 days. Ten of the patients with LGL were in terminal leukemic phase. All patients had received previous chemotherapy, most with multiple regimens. Patients received a mean of 5.1 cycles (range 1-9). 4 patients-one with CLL and 3 with LGL-achieved a complete remission, while 7 LGL and 3 CLL patients had a partial response. Two patients remain in complete remission 23 and 25 months after completion of therapy. One patient underwent successful autologous bone marrow transplantation after achieving a complete remission, while two others had marrow cryopreserved during complete remission. The drug was well tolerated and toxicity was mild. In 9 of the 122 given cycles patients required hospitalisation. In conclusion, Fludarabine is active in refractory patients with CLL and LGL and induces complete and partial remissions in some. It seems that Fludarabine could be used as primary therapy in these disorders in the future.

引用

页码：173 / 175

页数：3

共 16 条

[1] Plunkett W., Gandhi V., Huang P., Fludara-bine: Pharmacokinetics, mechanisms of action and rationale for combination therapies, Semin. Oncol., 20, Suppl. 7, pp. 2-12, (1993)
[2] Leiby J.M., Snider K.M., Kraut E.H., Metz E.N., Malspeis L., Grever M.R., Phase II trial of 9-β-D-Arabinofuranosyl-2-fluroadenine 5′-Monophosphate in non-hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity, Cancer Res., 47, pp. 2719-2722, (1987)
[3] Keating M.J., Kantarjian H., Talpaz M., Flu-darabine: A new agent with major activity against chronic lymphocytic leukemia, Blood, 74, pp. 19-25, (1989)
[4] Hochster H., Cassileth P., Fludarabine phosphate therapy of non-hodgkin's lymphoma, Semin. Oncol., 17, Suppl. 8, pp. 63-85, (1990)
[5] Keating M.J., Fludarabine phosphate in the treatment of chronic lymphocytic leukemia, Semin. Oncol., 17, Suppl. 8, pp. 49-62, (1990)
[6] Hochster H.S., Kim K., Green M.D., Activity of fludarabine in previously treated non-hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Study Group, J. Clin. Oncol., 10, pp. 28-32, (1992)
[7] Redman J.R., Cabanillas E., Velasquez W.S., Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma, J. Clin. Oncol., 10, pp. 790-794, (1992)
[8] Zinzani P.L., Lauria F., Rondelli D., Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia, Eur. J. Haematol., 51, pp. 93-97, (1993)
[9] Pigaditou A., Rohatiner A.Z.S., Whelan J.S., Fludarabine in low-grade lymphoma, Semin. Oncol., 20, Suppl. 7, pp. 24-27, (1993)
[10] Anaissie E., Kontoyiannis D.P., Kantarjian H., Elting L., Robertson L.E., Keating M., Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone, Ann. Intern. Med., 117, pp. 466-469, (1992)

← 1 2 →